Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 1, 2000, Pages 8-14

  Duncan, Gary E ^a   Miyamoto, Seiya ^a   Leipzig, Jeremy N ^a   Lieberman, Jeffrey A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG UPTAKE; GENE DISRUPTION; HIPPOCAMPUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR POTENTIAL; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BENZODIAZEPINES; BRAIN; BRAIN CHEMISTRY; CLOZAPINE; DEOXYGLUCOSE; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE;

EID: 0034126858     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283:55-62.
2. Arvanov VL, Liang X, Schwartz J, Grossman S and Wang RY (1997) Clozapine and haloperidol modulate N-methyl-D-aspartate-and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234.
3. Arvanov VL and Wang RY (1999) Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther 289:1000-1006.
4. Bakshi VP and Geyer MA (1995) Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122:198-201.
5. Bakshi VP, Swerdlow NR and Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787-794.
6. Bradford DW, Chakos MH, Sheitman BB and Lieberman JA (1998) Atypical anti-psychotic drugs in treatment-refractory schizophrenia. Psychiatr Ann 28:618.
7. Corbett R, Camacho F, Woods AT, Herman LL, Fishkin RJ, Brooks K and Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120:67-74.
8. Duncan GE, Johnson KB and Breese GRT (1993) Topographic patterns of brain activity in response to swim stress: Assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J Neurosci 13:3932-3943.
9. Duncan GE, Leipzig JN, Mailman RB and Lieberman JA (1998b) Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812:65-75.
10. Duncan GE, Miyamoto S, Leipzig JN and Lieberman JA (1999) Comparison of brain metabolic activity patterns induced by ketamine, MK-801, and amphetamine in rats: Support for NMDA receptor involvement in responses to subanesthetic doses of ketamine. Brain Res 843:171-183.
11. Duncan GE, Moy SS, Knapp DJ, Mueller RA and Breese GR (1998a) Metabolic mapping of the rat brain after subanesthetic doses of ketamine: Potential relevance to schizophrenia. Brain Res 787:181-190.
12. Fanous A and Lindenmayer JP (1999) Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. J Clin Psychopharmacol 19:275-276.
13. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C and Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
14. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C and Ericsson B (1995) Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15:19S-23S.
15. Heimann SW (1999) High-dose olanzapine in an adolescent. J Am Acad Child Adolesc Psychiatry 38:496-497.
16. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA and Meert TF (1988) Pharmacology of risperidone (R64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685-693.
17. Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
18. Jentsch JD, Redmond DEJ, Elsworth JD, Taylor JR, Youngren KD and Roth RH (1997) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science (Wash DC) 277:953-955.
19. Kapur S, Zipursky RB and Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293.
20. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA and Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry 155:921-928.
21. Kinon BJ and Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs: A critical analysis. Psychopharmacology 124:2-34.
22. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MBJ and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
23. Lahti AC, Koffel B, LaPorte D and Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
24. Lieberman JA, Kane JM and Alvir JAJ (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91:415-433.
25. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D and Breier A (1997) Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry 42:664-668.
26. Malhotra AK, Finals DA, Weingartner H, Sirocco K, Missar CD, Pickar D and Breier A (1996) NMDA receptor function and human cognition - The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307.
27. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ and Leysen JE (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114:9-23.
28. Meltzer HY (1996) Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review. Br J Psychiatry 29 (Suppl):23-31.
29. Meltzer HY, Matsubara S and Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and Serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246.
30. Mountjoy CQ, Baldacchino AM and Stubbs JH (1999) British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 156: 158-159.
31. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C and Sedvall G (1995) D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449.
32. Olney JW and Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
33. Reich J (1999) Use of high-dose olanzapine in refractory psychosis. Am J Psychiatry 156:661.
34. Rollema H, Lu Y, Schmidt AW and Zorn SH (1997) Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338:R3-R5.
35. Sheitman BB, Lindgren JC, Early J and Sved M (1997) High-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 154:1626.
36. Stockton ME and Rasmussen K (1996) Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology 124:50-56.
37. Swerdlow NE, Bakshi VP and Geyer MA (1996) Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279:1290-1299.
38. Tauscher J, Kufferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brucke T and Kasper S (1999) In vivo I-123 IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 141: 175-181.
39. Varty GB, Bakshi VP and Geyer MA (1999) M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20: 311-321.
40. Wang RY and Liang X (1998) M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 19:74-85.
41. Zhang W and Bymaster FP (1999) The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D-1, D-2, D-3, 5HT(2A) and muscannic receptors. Psychopharmacology 141:267-278.